SG Americas Securities
SUPN icon

SG Americas Securities’s Supernus Pharmaceuticals SUPN Stock Holding History

SG Americas Securities’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.2M Sell
25,866
-351,347
-93% -$16.9M ﹤0.01% 1765
2026
Q1 		$19.5M Buy
377,213
+364,413
+2,847% +$18.6M 0.02% 551
2025
Q4 		$636K Buy
12,800
+2,447
+24% +$119K ﹤0.01% 2351
2025
Q3 		$495K Sell
10,353
-11,070
-52% -$446K ﹤0.01% 2128
2025
Q2 		$675K Buy
21,423
+3,752
+21% +$120K ﹤0.01% 1442
2025
Q1 		$579K Buy
17,671
+6,867
+64% +$243K ﹤0.01% 1649
2024
Q4 		$391K Buy
+10,804
New +$380K ﹤0.01% 1565
2024
Q3 		– Sell
-18,064
Closed -$483K – 3591
2024
Q2 		$483K Buy
18,064
+14,279
+377% +$414K ﹤0.01% 1702
2024
Q1 		$129K Buy
+3,785
New +$113K ﹤0.01% 2345
2023
Q4 		– Sell
-28,999
Closed -$800K – 3430
2023
Q3 		$800K Buy
+28,999
New +$883K 0.01% 1450
2023
Q1 		– Sell
-12,503
Closed -$446K – 3546
2022
Q4 		$446K Buy
12,503
+2,765
+28% +$96.1K 0.01% 1640
2022
Q3 		$330K Sell
9,738
-35,680
-79% -$1.16M ﹤0.01% 1911
2022
Q2 		$1.31M Sell
45,418
-12,084
-21% -$346K 0.01% 1060
2022
Q1 		$1.86M Sell
57,502
-23,672
-29% -$726K 0.01% 970
2021
Q4 		$2.37M Buy
81,174
+28,974
+56% +$879K 0.01% 957
2021
Q3 		$1.39M Buy
52,200
+41,750
+400% +$1.12M 0.01% 1614
2021
Q2 		$322K Buy
10,450
+2,772
+36% +$85K ﹤0.01% 2136
2021
Q1 		$201K Sell
7,678
-563
-7% -$15.7K ﹤0.01% 2680
2020
Q4 		$207K Sell
8,241
-13,425
-62% -$289K ﹤0.01% 2612
2020
Q3 		$452K Sell
21,666
-32,806
-60% -$745K ﹤0.01% 1695
2020
Q2 		$1.29M Buy
54,472
+32,448
+147% +$717K 0.01% 1165
2020
Q1 		$396K Buy
22,024
+8,753
+66% +$184K ﹤0.01% 2029
2019
Q4 		$315K Buy
13,271
+2,184
+20% +$53K ﹤0.01% 2154
2019
Q3 		$305K Sell
11,087
-6,198
-36% -$184K ﹤0.01% 2146
2019
Q2 		$572K Buy
17,285
+11,533
+201% +$395K ﹤0.01% 1803
2019
Q1 		$202K Sell
5,752
-72,633
-93% -$2.7M ﹤0.01% 2573
2018
Q4 		$2.6M Buy
78,385
+62,258
+386% +$2.68M 0.02% 696
2018
Q3 		$812K Sell
16,127
-675
-4% -$33.3K 0.01% 1839
2018
Q2 		$1.01M Buy
16,802
+13,496
+408% +$699K 0.01% 1434
2018
Q1 		$151K Sell
3,306
-4,018
-55% -$168K ﹤0.01% 2639
2017
Q4 		$292K Sell
7,324
-15,112
-67% -$597K ﹤0.01% 2194
2017
Q3 		$897K Buy
+22,436
New +$971K 0.01% 1342
2017
Q2 		– Sell
-6,164
Closed -$193K – 3503
2017
Q1 		$193K Sell
6,164
-14,460
-70% -$388K ﹤0.01% 2467
2016
Q4 		$521K Buy
+20,624
New +$461K ﹤0.01% 1670
2015
Q4 		– Sell
-11,322
Closed -$159K – 2973
2015
Q3 		$159K Buy
+11,322
New +$211K ﹤0.01% 1596
2015
Q2 		– Sell
-10,420
Closed -$126K – 2818
2015
Q1 		$126K Sell
10,420
-2,583
-20% -$24.4K ﹤0.01% 2141
2014
Q4 		$108K Buy
+13,003
New +$109K ﹤0.01% 2870

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

SG Americas Securities's SUPN Position: Q2 2026 in Review

SG Americas Securities reduced its Supernus Pharmaceuticals (SUPN) stake by 93% in Q2 2026, selling an estimated $16.9M and leaving 25,866 shares worth $1.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1765.

SG Americas Securities first reported a position in SUPN in Q4 2014 and has held it in 37 quarters since. The position peaked at $19.5M in Q1 2026. 332 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • SG Americas Securities held 25,866 shares of Supernus Pharmaceuticals worth $1.2M as of Q2 2026.
  • SG Americas Securities sold 351,347 Supernus Pharmaceuticals shares in Q2 2026, an estimated $16.9M.
  • Supernus Pharmaceuticals made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #1765 holding.
  • SG Americas Securities first reported a position in Supernus Pharmaceuticals in Q4 2014 and has held it in 37 quarters since.
  • SG Americas Securities's Supernus Pharmaceuticals position peaked at $19.5M in Q1 2026.
  • 332 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.